GSK Files Q2 Report Showing £8.4bn Sales and £1.9bn Savings Plan
GSK's 6-K restates second-quarter 2026 turnover of £8.4 billion, up 5%, alongside a three-year Accelerate Growth programme targeting £1.9 billion in annual savings by 2029.
GSK's 6-K restates second-quarter 2026 turnover of £8.4 billion, up 5%, alongside a three-year Accelerate Growth programme targeting £1.9 billion in annual savings by 2029.
Tadaa Technology will supply the AI backbone for a 1,000-acre solar farm feeding a data centre under a 25-year power arrangement, targeting $7.3M in annual revenue.
Alpha Compute has signed definitive agreements for Utica and Marcellus acreage with more than 75 wells, and plans to build a data center on the site.
Palisade Bio can start the Phase 2 ASCENTRA-CD trial of its oral PDE4 prodrug, with first dosing targeted for Q1 2027 and a primary readout in Q1 2028.
VERSATILE-002 results for PDS0101 plus pembrolizumab show 39.3 months median overall survival in checkpoint-inhibitor-naive HPV16-positive head and neck cancer.